BenchSci is a brand that helps scientists accelerate breakthrough discoveries and bring new treatments to patients faster. Founded in 2015 by Tom Leung, David Q. Chen, Elvis Wianda, and Liran Belenzon, BenchSci aims to exponentially increase the speed and quality of life-saving research and development.

With over 50,000 platform users and 330 reagent use cases identified, BenchSci has become a trusted resource in the scientific community. By teaching computers to read and understand experiments like biologists, BenchSci offers AI-assisted antibody selection, reducing experimental failure and improving research outcomes. Their enterprise AI solution combines experiment-specific text ML, proprietary vision ML models, and bioinformatics ontologies to provide searchable results in an intuitive user interface.

Counting more than 4,300 leading academic research institutions and 16 of the top 20 pharma companies as users, BenchSci has become a powerful tool in supporting scientists' experiment decisions. Through Project Butterfly, BenchSci has built the world's first objective map of disease biology, and they continue to push the boundaries of research with their ASCEND platform. With ASCEND, BenchSci aims to increase the speed and yield of the R&D portfolio by multiples, shaping the future of medicine development.

Join BenchSci in their mission to make a difference in scientific discovery and be part of their inspiring story